IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by iA Global Asset Management Inc.

iA Global Asset Management Inc. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 13,763 shares of the company’s stock after purchasing an additional 2,158 shares during the period. iA Global Asset Management Inc.’s holdings in IDEXX Laboratories were worth $5,690,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Empowered Funds LLC raised its position in shares of IDEXX Laboratories by 2.8% during the 3rd quarter. Empowered Funds LLC now owns 1,310 shares of the company’s stock worth $662,000 after purchasing an additional 36 shares during the last quarter. Meeder Asset Management Inc. raised its position in shares of IDEXX Laboratories by 616.0% during the 3rd quarter. Meeder Asset Management Inc. now owns 179 shares of the company’s stock worth $90,000 after purchasing an additional 154 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its position in shares of IDEXX Laboratories by 11.0% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 835 shares of the company’s stock worth $422,000 after purchasing an additional 83 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of IDEXX Laboratories by 0.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 40,300 shares of the company’s stock worth $20,360,000 after purchasing an additional 184 shares during the last quarter. Finally, Prospera Private Wealth LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $157,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on IDXX. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, March 15th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Finally, Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $420.62 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a market cap of $34.21 billion, a price-to-earnings ratio of 39.42, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a 50-day moving average price of $437.30 and a two-hundred day moving average price of $445.53.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.